Want to see HK:1477 full AI Analyst Report?
Ocumension Therapeutics (1477) AI Stock Analysis
Top Page
Ocumension Therapeutics
(HKEX:1477)
The score is driven primarily by improving financial trajectory—strong revenue growth, solid gross margin, and narrowing losses—offset by continued negative operating/free cash flow and ongoing net losses. Technical signals are also weak with the stock trading below major moving averages and negative MACD, while valuation is constrained by the negative P/E and lack of dividend support.
Ocumension Therapeutics (1477) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 3.83B
- Dividend Yield
- ―
- Average Volume (3M)
- 376.87K
- Price to Earnings (P/E)
- -26.5
- Beta (1Y)
- 1.08
- Revenue Growth
- 77.55%
- EPS Growth
- 50.34%
- Country
- Hong Kong
- Employees
- 608
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Ocumension Therapeutics Business Overview & Revenue Model
Company Description
Based in the People's Republic of China, Ocumension Therapeutics functions as a dedicated ophthalmic pharmaceutical platform. This company, along with its subsidiaries, is committed to the research, progression, and market introduction of therapeutic...
How the Company Makes Money
Ocumension Therapeutics primarily makes money by commercializing ophthalmic prescription drugs, generating revenue from product sales to hospitals, pharmacies, and other medical distribution channels in China. A key component of its business model is...
Ocumension Therapeutics Financial Statement Overview
Summary
Revenue growth is strong and accelerating (2025 revenue up ~44% vs. 2024) with a solid gross margin (~44%), and losses have narrowed. However, profitability remains negative (net margin about -20% with negative EBIT/EBITDA) and cash flow is still a major weakness with consistently negative operating and free cash flow (about -359M in 2025), indicating continued reliance on funding.
Income Statement
46NeutralBalance Sheet
78PositiveCash Flow
41Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 934.03M | 804.35M | 417.31M | 246.37M | 158.96M | 56.15M |
| Gross Profit | 440.78M | 360.92M | 225.06M | 144.37M | 102.92M | 36.94M |
| EBITDA | 27.27M | -16.47M | -176.48M | -320.62M | -359.98M | -245.53M |
| Net Income | -125.52M | -158.82M | -268.27M | -379.79M | -402.64M | -259.99M |
Balance Sheet | ||||||
| Total Assets | 4.12B | 4.09B | 3.97B | 3.27B | 3.04B | 3.33B |
| Cash, Cash Equivalents and Short-Term Investments | 268.31M | 402.63M | 769.21M | 1.05B | 1.29B | 1.77B |
| Total Debt | 288.55M | 187.62M | 25.78M | 137.98M | 29.58M | 11.21M |
| Total Liabilities | 499.24M | 410.38M | 200.19M | 351.03M | 295.04M | 222.88M |
| Stockholders Equity | 3.62B | 3.68B | 3.77B | 2.92B | 2.75B | 3.11B |
Cash Flow | ||||||
| Free Cash Flow | -274.38M | -358.65M | -408.97M | -539.79M | -510.66M | -861.66M |
| Operating Cash Flow | -12.83M | -105.29M | -178.83M | -177.93M | -200.66M | -196.85M |
| Investing Cash Flow | -376.63M | -361.46M | 275.91M | -259.78M | 229.15M | -1.35B |
| Financing Cash Flow | 203.96M | 118.04M | -213.79M | 108.66M | -9.22M | 668.85M |
Ocumension Therapeutics Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1477, the sentiment is Negative. The current price of 4.79 is below the 20-day moving average (MA) of 4.84, below the 50-day MA of 5.09, and below the 200-day MA of 6.13, indicating a bearish trend. The MACD of -0.15 indicates Negative momentum. The RSI at 47.70 is Neutral, neither overbought nor oversold. The STOCH value of 51.99 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1477.
Ocumension Therapeutics Peers Comparison
Overall Rating
HK:218157Neutral
HK:662255Neutral- HK:147750Neutral
HK:217940Underperform
HK:662837Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:2181 | 57Neutral | HKD 1.79B | 17.80 | 48.25% | ― | 88.38% | ― |
| HK:6622 | 55Neutral | HKD 1.11B | -4.50 | -14.41% | ― | 2.56% | 20.20% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HK:1477 | 50Neutral | HKD 3.91B | -26.50 | -3.44% | ― | 77.55% | 50.34% |
| HK:2179 | 40Underperform | HKD 2.49B | -4.41 | -79.24% | ― | -82.46% | 41.19% |
| HK:6628 | 37Underperform | HKD 327.59M | -1.65 | -27.54% | ― | 215.14% | 40.49% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:1477 | Ocumension Therapeutics | 4.79 | -3.67 | -43.38% | |
| HK:2179 | Jiangsu Recbio Technology Co., Ltd. Class H | 4.00 | -2.99 | -42.78% | |
| HK:2181 | Mabpharm Limited | 0.43 | -0.09 | -16.35% | |
| HK:6622 | Zhaoke Ophthalmology Ltd. | 2.02 | -1.13 | -36.03% | |
| HK:6628 | Transcenta Holding Limited | 0.73 | -2.31 | -75.90% | |
| HK:6955 | Shandong Boan Biotechnology Company., Limited. Class H | 3.15 | -7.47 | -70.34% |
Ocumension Therapeutics Corporate Events
Ocumension Wins NMPA Green Light for Local Production of Uveitis Implant
Ocumension Therapeutics has secured approval from China’s National Medical Products Administration to manufacture its fluocinolone acetonide intravitreal implant, OT-401 (Youshiying), in mainland China rather than relying solely on overseas pro...
Ocumension Phase III Myopia Drug OT-101 Hits Primary Goal in China Cohort
Ocumension Therapeutics reported topline Month 36 results from a global, multi-centre Phase III trial of OT-101, its 0.01% atropine sulfate eye drops for pediatric myopia, involving 678 children and adolescents across eight countries. The primary end...
Ocumension’s Glaucoma Drug OT-301 Wins NDA Acceptance in China
Ocumension Therapeutics has announced that China’s National Medical Products Administration has accepted its new drug application for OT-301, an ophthalmic solution intended to lower intraocular pressure in patients with open-angle glaucoma or...
Ocumension Completes Phase III Patient Enrollment for Alcon-Developed Dry Eye Drug in China
Ocumension Therapeutics has completed enrollment of 398 patients in a Phase III clinical trial in China for OT-211, branded as TRYPTYR acoltremon eye drop, a 0.003% TRPM8 agonist previously approved by the U.S. FDA for treating signs and symptoms of...
Ocumension Advances China Localization of Key Eye Drug as NMPA Accepts Registration
Ocumension Therapeutics said China’s Center for Drug Evaluation has accepted its domestically produced dexamethasone intraocular suspension for drug registration as a Class 4 chemical drug, a localized version of its key product OT-502 (DEXYCU/...
Ocumension Advances OT-202 Dry Eye Drug With First Phase III Patient in China
Ocumension Therapeutics has enrolled the first patient in a Phase III clinical trial in China for OT-202, a first-in-class dual Syk/VEGFR-2 inhibitor for moderate to severe dry eye disease. The trial milestone underscores the company’s progress...
Ocumension Narrows Loss as Ophthalmic Portfolio Fuels Double-Digit Revenue Growth
Ocumension Therapeutics reported a 44.1% year-on-year increase in revenue to RMB423.7 million for the six months ended June 30, 2026, driven by strong sales of core ophthalmic brands and higher royalty income from the commercialization of Boyoujing....
Ocumension Redirects Remaining IPO Funds Toward Working Capital
Ocumension Therapeutics has disclosed an updated allocation plan for the proceeds from its 2020 Hong Kong initial public offering, after having utilized about HK$1.52 billion, or 92.4%, of the HK$1.65 billion it raised. As of June 30, 2026, approxima...
Ocumension Sets August Board Meeting to Approve Interim Results and Consider Dividend
Ocumension Therapeutics has scheduled a board meeting for August 28, 2026 to review and approve the interim financial results for the six months ended June 30, 2026. The board will also consider whether to recommend an interim dividend, a decision th...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 17, 2026